132 related articles for article (PubMed ID: 12641727)
21. Neurotoxicity but not infectivity of prion proteins can be induced reversibly in vitro.
Post K; Brown DR; Groschup M; Kretzschmar HA; Riesner D
Arch Virol Suppl; 2000; (16):265-73. PubMed ID: 11214930
[TBL] [Abstract][Full Text] [Related]
22. Toxicity of novel C-terminal prion protein fragments and peptides harbouring disease-related C-terminal mutations.
Daniels M; Cereghetti GM; Brown DR
Eur J Biochem; 2001 Dec; 268(23):6155-64. PubMed ID: 11733010
[TBL] [Abstract][Full Text] [Related]
23. Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231.
Corsaro A; Thellung S; Chiovitti K; Villa V; Simi A; Raggi F; Paludi D; Russo C; Aceto A; Florio T
Neurotox Res; 2009 Feb; 15(2):138-54. PubMed ID: 19384577
[TBL] [Abstract][Full Text] [Related]
24. Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106-126.
Thellung S; Florio T; Corsaro A; Arena S; Merlino M; Salmona M; Tagliavini F; Bugiani O; Forloni G; Schettini G
Int J Dev Neurosci; 2000; 18(4-5):481-92. PubMed ID: 10817932
[TBL] [Abstract][Full Text] [Related]
25. Nonspecific prion protein-nucleic acid interactions lead to different aggregates and cytotoxic species.
Macedo B; Millen TA; Braga CA; Gomes MP; Ferreira PS; Kraineva J; Winter R; Silva JL; Cordeiro Y
Biochemistry; 2012 Jul; 51(27):5402-13. PubMed ID: 22691027
[TBL] [Abstract][Full Text] [Related]
26. In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression.
Chabry J; Ratsimanohatra C; Sponne I; Elena PP; Vincent JP; Pillot T
J Neurosci; 2003 Jan; 23(2):462-9. PubMed ID: 12533606
[TBL] [Abstract][Full Text] [Related]
27. Assemblages of prion fragments: novel model systems for understanding amyloid toxicity.
Satheeshkumar KS; Murali J; Jayakumar R
J Struct Biol; 2004 Nov; 148(2):176-93. PubMed ID: 15477098
[TBL] [Abstract][Full Text] [Related]
28. Neurotoxicity of the putative transmembrane domain of the prion protein.
Haïk S; Peyrin JM; Lins L; Rosseneu MY; Brasseur R; Langeveld JP; Tagliavini F; Deslys JP; Lasmézas C; Dormont D
Neurobiol Dis; 2000 Dec; 7(6 Pt B):644-56. PubMed ID: 11114262
[TBL] [Abstract][Full Text] [Related]
29. Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates.
Qahwash I; Weiland KL; Lu Y; Sarver RW; Kletzien RF; Yan R
J Biol Chem; 2003 Jun; 278(25):23187-95. PubMed ID: 12684519
[TBL] [Abstract][Full Text] [Related]
30. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives.
Poli G; Ponti W; Carcassola G; Ceciliani F; Colombo L; Dall'Ara P; Gervasoni M; Giannino ML; Martino PA; Pollera C; Villa S; Salmona M
Arzneimittelforschung; 2003; 53(12):875-88. PubMed ID: 14750496
[TBL] [Abstract][Full Text] [Related]
31. Self-Replication of Prion Protein Fragment 89-230 Amyloid Fibrils Accelerated by Prion Protein Fragment 107-143 Aggregates.
Sneideris T; Ziaunys M; Chu BK; Chen RP; Smirnovas V
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049945
[TBL] [Abstract][Full Text] [Related]
32. Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106-126.
Kanapathipillai M; Ku SH; Girigoswami K; Park CB
Biochem Biophys Res Commun; 2008 Jan; 365(4):808-13. PubMed ID: 18039468
[TBL] [Abstract][Full Text] [Related]
33. Core structure of amyloid fibrils formed by residues 106-126 of the human prion protein.
Walsh P; Simonetti K; Sharpe S
Structure; 2009 Mar; 17(3):417-26. PubMed ID: 19278656
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein 104 inhibited the fibrillization of prion peptide 106-126 and disassembled prion peptide 106-126 fibrils in vitro.
Liu YH; Han YL; Song J; Wang Y; Jing YY; Shi Q; Tian C; Wang ZY; Li CP; Han J; Dong XP
Int J Biochem Cell Biol; 2011 May; 43(5):768-74. PubMed ID: 21296677
[TBL] [Abstract][Full Text] [Related]
35. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment.
Brown DR; Schmidt B; Kretzschmar HA
Nature; 1996 Mar; 380(6572):345-7. PubMed ID: 8598929
[TBL] [Abstract][Full Text] [Related]
36. PrP and beta-amyloid fragments activate different neurotoxic mechanisms in cultured mouse cells.
Brown DR; Herms JW; Schmidt B; Kretzschmar HA
Eur J Neurosci; 1997 Jun; 9(6):1162-9. PubMed ID: 9215699
[TBL] [Abstract][Full Text] [Related]
37. The interaction of humic substances with the human prion protein fragment 90-231 affects its protease K resistance and cell internalization.
Corsaro A; Anselmi C; Polano M; Aceto A; Florio T; De Nobili M
J Biol Regul Homeost Agents; 2010; 24(1):27-39. PubMed ID: 20385069
[TBL] [Abstract][Full Text] [Related]
38. Oxidation reduces the fibrillation but not the neurotoxicity of the prion peptide PrP106-126.
Bergström AL; Chabry J; Bastholm L; Heegaard PM
Biochim Biophys Acta; 2007 Sep; 1774(9):1118-27. PubMed ID: 17707142
[TBL] [Abstract][Full Text] [Related]
39. Prion peptide 106-126 as a model for prion replication and neurotoxicity.
Singh N; Gu Y; Bose S; Kalepu S; Mishra RS; Verghese S
Front Biosci; 2002 Apr; 7():a60-71. PubMed ID: 11897566
[TBL] [Abstract][Full Text] [Related]
40. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity.
Nieznanski K; Choi JK; Chen S; Surewicz K; Surewicz WK
J Biol Chem; 2012 Sep; 287(40):33104-8. PubMed ID: 22915585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
